Compare PSN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | RYTM |
|---|---|---|
| Founded | 1944 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.4B |
| IPO Year | 2019 | 2017 |
| Metric | PSN | RYTM |
|---|---|---|
| Price | $66.80 | $89.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $84.00 | ★ $129.43 |
| AVG Volume (30 Days) | ★ 1.3M | 712.7K |
| Earning Date | 05-13-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.77 | ★ 28.34 |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $6,364,245,000.00 | N/A |
| Revenue This Year | $6.45 | $58.38 |
| Revenue Next Year | $7.69 | $83.95 |
| P/E Ratio | $30.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.20 | $45.91 |
| 52 Week High | $89.50 | $122.20 |
| Indicator | PSN | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 35.17 |
| Support Level | $66.62 | $83.98 |
| Resistance Level | $70.03 | $96.92 |
| Average True Range (ATR) | 2.36 | 5.65 |
| MACD | 0.36 | -0.86 |
| Stochastic Oscillator | 85.62 | 15.42 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.